1 Min Read
Feb 16 (Reuters) - HANSA MEDICAL AB:
* HANSA MEDICAL RECEIVES FDA ORPHAN DRUG DESIGNATION FOR IDES AND THE TREATMENT OF GUILLAIN-BARRÉ SYNDROME Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.